Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial
…, C Tanasescu, E Nasonov, JL Lan, L Pineda, ZJ Zhong… - The Lancet, 2011 - thelancet.com
Background Systemic lupus erythematosus is a heterogeneous autoimmune disease that is
associated with B-cell hyperactivity, autoantibodies, and increased concentrations of B-…
associated with B-cell hyperactivity, autoantibodies, and increased concentrations of B-…
[HTML][HTML] Nusinersen versus sham control in infantile-onset spinal muscular atrophy
…, AM Glanzman, K Bishop, ZJ Zhong… - … England Journal of …, 2017 - Mass Medical Soc
Background Spinal muscular atrophy is an autosomal recessive neuromuscular disorder that
is caused by an insufficient level of survival motor neuron (SMN) protein. Nusinersen is an …
is caused by an insufficient level of survival motor neuron (SMN) protein. Nusinersen is an …
A phase III, randomized, placebo‐controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus …
…, EM Ginzler, DR Hough, ZJ Zhong… - Arthritis & …, 2011 - Wiley Online Library
Objective To assess the efficacy/safety of the B lymphocyte stimulator inhibitor belimumab
plus standard therapy compared with placebo plus standard therapy in active systemic lupus …
plus standard therapy compared with placebo plus standard therapy in active systemic lupus …
A phase II, randomized, double‐blind, placebo‐controlled, dose‐ranging study of belimumab in patients with active systemic lupus erythematosus
…, V Fernandez, MR Chevrier, ZJ Zhong… - Arthritis Care & …, 2009 - Wiley Online Library
Objective To assess the safety, tolerability, biologic activity, and efficacy of belimumab in
combination with standard of care therapy (SOC) in patients with active systemic lupus …
combination with standard of care therapy (SOC) in patients with active systemic lupus …
Novel evidence‐based systemic lupus erythematosus responder index
…, A Weinstein, MR Chevrier, ZJ Zhong… - Arthritis Care & …, 2009 - Wiley Online Library
Objective To describe a new systemic lupus erythematosus (SLE) responder index (SRI) based
on a belimumab phase II SLE trial and demonstrate its potential utility in SLE clinical trials…
on a belimumab phase II SLE trial and demonstrate its potential utility in SLE clinical trials…
Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response
…, DA Roth, BN Ji, CS Kleoudis, ZJ Zhong… - Annals of the …, 2012 - ard.bmj.com
Objectives To identify factors that predict response to belimumab treatment in the phase 3
BLISS trials of autoantibody-positive systemic lupus erythematosus (SLE) and further analyse …
BLISS trials of autoantibody-positive systemic lupus erythematosus (SLE) and further analyse …
Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus
…, L Pineda, TS Migone, ZJ Zhong… - Arthritis & …, 2012 - Wiley Online Library
Objective To assess the effects of the B lymphocyte stimulator (BLyS)–specific inhibitor
belimumab on immunologic biomarkers, including B cell and T cell populations, and …
belimumab on immunologic biomarkers, including B cell and T cell populations, and …
Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus …
Objective To evaluate the effects of belimumab versus placebo, plus standard systemic
lupus erythematosus (SLE) therapy, on organ domain-specific SLE disease activity. Methods …
lupus erythematosus (SLE) therapy, on organ domain-specific SLE disease activity. Methods …
Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials
…, SV Navarra, R Cervera, ZJ Zhong… - Arthritis & …, 2013 - Wiley Online Library
Objective To identify predictors of moderate‐to‐severe systemic lupus erythematosus (SLE)
flare in 562 patients treated with standard therapy alone in phase III belimumab trials, and to …
flare in 562 patients treated with standard therapy alone in phase III belimumab trials, and to …
Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus
…, JD McKay, WJ McCune, ZJ Zhong… - The Journal of …, 2014 - jrheum.org
Objective. To evaluate the efficacy/safety of belimumab plus standard therapy in patients (n
= 449) with active systemic lupus erythematosus (SLE) treated up to 7 years (n = 177 …
= 449) with active systemic lupus erythematosus (SLE) treated up to 7 years (n = 177 …